• Please log in or register to access this feature.

AASLD Practice Guideline

You have full text access to this OnlineOpen article

Management of adult patients with ascites due to cirrhosis: An update†‡§

  1. Bruce A. Runyon¶,*

Article first published online: 23 JAN 2009

DOI: 10.1002/hep.22853

Issue

Hepatology

Hepatology

Volume 49, Issue 6, pages 2087–2107, June 2009

Additional Information

How to Cite

Runyon, B. A. (2009), Management of adult patients with ascites due to cirrhosis: An update. Hepatology, 49: 2087–2107. doi: 10.1002/hep.22853

Author Information

  1. Liver Service, Loma Linda University Medical Center, Loma Linda, CA

  1. fax: 909-558-0274

*Liver Service, Loma Linda University Medical Center, 11234 Anderson Street, Room 1556, Loma Linda, CA 92354

  1. †

    All American Association for the Study of Liver Diseases (AASLD) Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material.

  2. ‡

    This is a revised and updated guideline based on the previously published version. (HEPATOLOGY 2004;39:841–856).

  3. §

    Potential conflict of interest: Dr. Runyon is a consultant for Novashunt.

  4. fax: 909-558-0274

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 23 JAN 2009
  3. Accepted manuscript online: 23 JAN 2009 12:00AM EST
  4. Manuscript Accepted: 16 JAN 2009
  5. Manuscript Received: 15 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (248K)

References

  • 1
    Eddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines: The Explicit Approach. Philadelphia, PA: American College of Physicians; 1996.
  • 2
    American Gastroenterological Association. Policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925–926.
  • 3
    American Heart Association. Methodology Manual. http://www.heart.org/presenter.jhtml?identifier=3039683. Accessed January 2009.
  • 4
    Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493–498.
  • 5
    Minino AM, Heron MP, Smith BK. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006; 54: 1–7.
  • 6
    Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987; 7: 12–18.
    Direct Link:
  • 7
    Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, de la Cuesta FS, Fraile JM, et al. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol 2002; 58: 435–440.
  • 8
    Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38: S69–S89.
  • 9
    Planas R, Montoliu S, Balleste B, Rivera M, Miguel M, Masnou H, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385–1394.
  • 10
    Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215–220.
  • 11
    Poonwala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. HEPATOLOGY 2000; 32: 689–692.
    Direct Link:
  • 12
    de Kerguenec C, Hillaire S, Molinie V, Gardin C, Degott C, Erlinger S, et al. Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol 2001; 96: 852–857.
  • 13
    Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical exam in the diagnosis of suspected ascites. JAMA 1982; 247: 1164–1166.
  • 14
    Sheer TA, Joo E, Runyon BA. Usefulness of serum pro-brain-type natriuretic peptide in distinguishing ascites due to cirrhosis from ascites due to heart failure. J Clin Gastroenterol. In press.
  • 15
    Oray-Schrom P, St Martin D, Bartelloni P, Amoateng-Adjepong Y. Giant nonpancreatic pseudocyst causing acute anuria. Am J Gastroenterol 2002; 34: 160–163.
  • 16
    Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337–342.
  • 17
    Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 8th ed. Philadelphia, PA: Saunders; 2006: 1935–1964.
  • 18
    Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41–48.
  • 19
    Runyon BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986; 146: 2259–2261.
  • 20
    Webster ST, Brown KL, Lucey MR, Nostrant TT. Hemorrhagic complications of large volume abdominal paracentesis. Am J Gastroenterol 1996; 92: 366–368.
  • 21
    Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver failure. Aliment Pharmacol Ther 2005; 21: 525–529.
    Direct Link:
  • 22
    Grabau CM, Crago SF, Hoff LK, Simon JA, Melton CA, Ott BJ, et al. Performance standards for therapeutic abdominal paracentesis. HEPATOLOGY 2004; 40: 484–488.
    Direct Link:
  • 23
    Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4: 721–723.
    Direct Link:
  • 24
    Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. HEPATOLOGY 2006; 44: 1039–1046.
    Direct Link:
  • 25
    Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 1581–1586.
    Direct Link:
  • 26
    Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006; 23: 115–120.
    Direct Link:
  • 27
    Sakai H, Sheer TA, Mendler MH, Runyon BA. Choosing the location for non-image guided abdominal paracentesis. Liver Int 2005; 25: 984–986.
    Direct Link:
  • 28
    Oelsner DH, Caldwell SH, Coles M, Driscoll CJ. Subumbilical midline vascularity of the abdominal wall in portal hypertension observed at laparoscopy. Gastrointest Endosc 1998; 47: 388–390.
  • 29
    Castellote J, Lopez C, Gornals J, Tremosa G, Farina ER, Baliellas C, et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. HEPATOLOGY 2003; 37: 893–896.
    Direct Link:
  • 30
    Runyon BA. Strips and tubes: refining the diagnosis of spontaneous bacterial peritonitis. HEPATOLOGY 2003; 37: 745–747.
    Direct Link:
  • 31
    Nousbaum JP, Cadranel JF, Nahon P, Khac EN, Moreau R, Thevenot T, et al. Diagnostic accuracy of the multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. HEPATOLOGY 2007; 45: 1275–1281.
    Direct Link:
  • 32
    Angeloni S, Nicolini G, Merli M, Nicalao F, Pinto G, Aronne T, et al. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol 2003; 98: 1844–1848.
    Direct Link:
  • 33
    Akriviadis EA, Runyon BA. The value of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990; 98: 127–133.
  • 34
    Wu SS, Lin OS, Chen Y-Y, Hwang KL, Soon MS, Keeffe EB. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. J Hepatol 2001; 34: 215–221.
  • 35
    Hoefs JC. Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med 1983; 102: 260–273.
  • 36
    Jeffries MA, Stern MA, Gunaratnum NT, Fontana RJ. Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis. Am J Gastroenterol 1999; 94: 2972–2976.
    Direct Link:
  • 37
    Evans LT, Kim R, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. HEPATOLOGY 2003; 37: 897–901.
    Direct Link:
  • 38
    Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. HEPATOLOGY 1988; 8: 1104–1109.
    Direct Link:
  • 39
    Decker D, Stratmann H, Springer W, Schwering H, Varnai N, Bollman R. Benign and malignant cells in effusions: diagnostic value of image DNA cytometry in comparison to cytological analysis. Pathol Res Pract 1998; 194: 791–795.
  • 40
    Kielhorn E, Schofield K, Rimm DL. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer 2002; 94: 205–211.
    Direct Link:
  • 41
    Hillebrand DJ, Runyon BA, Yasmineh WG, Rynders G. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. HEPATOLOGY 1996; 24: 1408–1412.
    Direct Link:
  • 42
    Cappell MS, Shetty V. A multicenter, case-controlled study of the clinical presentation and etiology of ascites and of the safety and efficacy of diagnostic abdominal paracentesis in HIV seropositive patients. Am J Gastroenterol 1994; 89: 2172–2177.
  • 43
    Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95: 1351–1355.
  • 44
    Runyon BA, Antillon MR, Akriviadis EA, McHutchison JG. Bedside inoculation of blood culture bottles is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol 1990; 28: 2811–2812.
  • 45
    Runyon BA. Malignancy-related ascites and ascitic fluid humoral tests of malignancy. J Clin Gastroenterol 1994; 18: 94–98.
  • 46
    Zuckerman E, Lanir A, Sabo E, Rosenvald-Zuckerman T, Matter I, Yeshuran D, et al. Cancer antigen 125: a sensitive marker of ascites in patients with cirrhosis. Am J Gastroenterol 1999; 94: 1613–1618.
    Direct Link:
  • 47
    Veldt BJ, Laine F, Guillogomarc'h A, Lauvin L, Boudjema K, Messner M, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93–98.
  • 48
    Yao F, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301–307.
  • 49
    Eisenmenger WJ, Ahrens EH, Blondheim SH, Kunkel HG. The effect of rigid sodium restriction in patients with cirrhosis of the liver and ascites. J Lab Clin Med 1949; 34: 1029–1038.
  • 50
    Eisenmenger WJ, Blondheim SH, Bongiovanni AM, Kunkel HG. Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest 1950; 29: 1491–1499.
  • 51
    Stiehm AJ, Mendler MH, Runyon BA. Detection of diuretic-resistance or diuretic-sensitivity by the spot urine Na/K ratio in 729 specimens from cirrhotics with ascites: approximately 90% accuracy as compared to 24-hr urine Na excretion [Abstract]. HEPATOLOGY 2002; 36: 222A.
  • 52
    Abbasoglu O, Goldstein RM, Vodapally MS, Jennings LW, Levy MF, Husberg BS, et al. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant 1998; 12: 263–269.
  • 53
    Angeli P, Wong F, Watson H, Gines P, Castelpoggi CHF, Ferraz ML, et al. Hyponatremia in cirrhosis: results of a patient population survery. HEPATOLOGY 2006; 44: 1535–1542.
    Direct Link:
  • 54
    Sterns RH. Severe hyponatremia: treatment and outcome. Ann Intern Med 187; 107: 656–664.
  • 55
    Wong F, Blei AT, Blendis LM, Thulavath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. HEPATOLOGY 2003; 37: 182–191.
    Direct Link:
  • 56
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099–2112.
  • 57
    Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992; 102: 1680–1685.
  • 58
    Perez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, et al. Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 1983; 84: 961–968.
  • 59
    Sawhney VK, Gregory PB, Swezey SE, Blaschke TF. Furosemide disposition in cirrhotic patients. Gastroenterology 1981; 81: 1012–1016.
  • 60
    Daskalopoulos G, Laffi G, Morgan T, Pinzani G, Harley H, Reynolds T, et al. Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. Gastroenterology 1987; 92: 1859–1863.
  • 61
    Santos J, Planas R, Pardo A, Durandez R, Cabre E, Morillas RM, et al. Spironolactone alone or in combination with furosemide in treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003; 39: 187–192.
  • 62
    Mazza E, Angeli P, Fasolato S, Galioto A, Zola E, Guarda S, et al. Sequential versus “ab initio” combined diuretic treatment of moderate ascites in cirrhotic patients: final results of a randomized controlled multicenter clinical study [Abstract]. Gastroenterology 2007; 132: A796.
  • 63
    Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 1989; 321: 1632–1638.
  • 64
    Angeli P, Pria MD, De Bei E, Albino G, Caregaro L, Merkel C, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. HEPATOLOGY 1994; 19: 72–79.
    Direct Link:
  • 65
    Ginsberg DJ, Saad A, Gabuzda GJ. Metabolic studies with the diuretic triamterene in patients with cirrhosis and ascites. N Engl J Med 1964; 271: 1229–1235.
  • 66
    Hillenbrand P, Sherlock S. Use of metolazone in the treatment of ascites due to liver disease. Br Med J 1971; 4: 266–270.
  • 67
    McHutchison JG, Pinto PC, Reynolds TB. Hydrochlorothiazide as a third diuretic in cirrhosis with refractory ascites [Abstract]. HEPATOLOGY 1989; 10: 719.
  • 68
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplenerone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
  • 69
    Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. HEPATOLOGY 2001; 33: 28–31.
    Direct Link:
  • 70
    Toniutto P, Pirisi M, Fabris C, Apollonio L, Sereti K, Baretolli EG. The significance of the furosemide test for predicting ascites control by diuretics in cirrhosis: a comparison with volume expansion and octreotide infusion. Dig Dis Sci 2006; 51: 1992–1997.
  • 71
    Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006; 12: 1403–1407.
  • 72
    Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90: 1827–1833.
  • 73
    Peltekian KM, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in cirrhotic patients with diuretic-resistant ascites. Am J Gastroenterol 1997; 92: 394–399.
  • 74
    Tito L, Gines P, Arroyo V, Planas R, Panes J, Rimola A, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990; 98: 146–151.
  • 75
    Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 1987; 93: 234–241.
  • 76
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996; 23: 164–176.
    Direct Link:
  • 77
    Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77: 215–222.
  • 78
    Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493–1502.
  • 79
    Gines A, Fernandez-Esparrach G, Monescillo A, Vola C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002–1010.
  • 80
    Salo J, Gines A, Gines P, Piera C, Jimenez W, Guevara M, et al. Effect of therapeutic paracentesis on plasma volume and transvascular escape of albumin in patients with cirrhosis. J Hepatol 1997; 27: 645–653.
  • 81
    Rothschild M, Oratz M, Evans C, Schreiber SS. Alterations in albumin metabolism after serum and albumin infusions. J Clin Invest 1964; 43: 1874–1880.
  • 82
    Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet 1962; ii: 1125–1129.
  • 83
    Pietrangelo A, Panduro A, Chowdhury JR, Shafritz DA. Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat. J Clin Invest 1992; 89: 1755–1760.
  • 84
    Haynes GR, Navickis RJ, Wilkes MM. Albumin administration—what is the evidence of clinical benefit? A systematic review of randomized controlled trials. Eur J Anaesth 2003; 20: 771–793.
  • 85
    American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med 2004; 170: 1247–1259.
  • 86
    Cabrera J, Inglada L, Quintero E, Jimenez W, Losada A, Mayor J, et al. Large-volume paracentesis and intravenous saline: effects on the renin-angiotensin system. HEPATOLOGY 1991; 14: 1025–1028.
    Direct Link:
  • 87
    Christidis C, Mak F, Ramos J, Senejoux A, Callard P, Navarro R, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001; 35: 726–732.
  • 88
    Singh V, Kumar R, Kanwal C, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2006; 21: 303–307.
    Direct Link:
  • 89
    Choi CH, Ahn SH, Kim DY, Lee SK, Park JY, Chon CH, et al. Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study. J Gastroenterol Hepatol 2005; 20: 1215–1222.
    Direct Link:
  • 90
    Heuman DM, Abou-assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. HEPATOLOGY 2004; 40: 802–810.
  • 91
    Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Diebert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–1707.
  • 92
    Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839–1847.
  • 93
    Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25: 135–144.
  • 94
    Sanyal AJ, Genning C, Reddy RK, Wong F, Kowdley K, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003; 124: 634–641.
  • 95
    Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS vs. paracentesis plus albumin in cirrhosis with severe ascites. HEPATOLOGY 2004; 40: 629–635.
    Direct Link:
  • 96
    Saab S, Nieto JM, Ky D, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004; 3: CD004889.
  • 97
    Deltenre P, Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005; 25: 349–356.
    Direct Link:
  • 98
    Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43: 990–996.
  • 99
    D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 1282–1293.
  • 100
    Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006; 4: CD004889.
  • 101
    Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825–834.
  • 102
    Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. HEPATOLOGY 1997; 26: 1131–1137.
  • 103
    Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. HEPATOLOGY 1994; 19: 129–132.
    Direct Link:
  • 104
    Rabie R, Cazzaniga M, Salerno F, Wong F. The effect of cirrhotic cardiomyopathy on the post-TIPS outcome of patients treated for complications of portal hypertension [Abstract]. HEPATOLOGY 2006; 44: 444A.
  • 105
    Michl P, Gulberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure. Scand J Gastroenterol 2000; 35: 654–657.
  • 106
    Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469–475.
  • 107
    Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, et al. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. HEPATOLOGY 2003; 38: 1043–1050.
  • 108
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000; 31: 864–871.
    Direct Link:
  • 109
    Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. HEPATOLOGY 2005; 41: 1–15.
    Direct Link:
  • 110
    Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 829–835.
  • 111
    Rosemurgy AS, Zervos EE, Clark WC, Thometz DP, Black TJ, Zweibel BR, et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004; 239: 883–891.
  • 112
    Park JS, Won JY, Park SI, Park SJ, Lee DY. Percutaneous peritoneovenous shunt creation for the treatment of benign and malignant refractory ascites. J Vasc Interv Radiol 2001; 12: 1445–1448.
  • 113
    Rosenblum DI, Geisenger MA, Newman JS, Boden TM, Markowitz D, Powell D, et al. Use of subcutaneous venous access ports to treat refractory ascites. J Vasc Interv Radiol 2001; 12: 1343–1346.
  • 114
    Rozenblit GN, Del Guercio LRM, Rundback JH, Poplausky MR, Lebovics E. Peritoneal-urinary drainage for treatment of refractory ascites: a pilot study. J Vasc Interv Radiol 1998; 9: 998–1005.
  • 115
    Trotter J, Pieramici E, Everson GT. Chronic albumin infusions to achieve dieresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS). Dig Dis Sci 2005; 50: 1356–1360.
  • 116
    Lenaerts A, Codden T, Meunier J-C, Henry J-P, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. HEPATOLOGY 2006; 44: 844–849.
    Direct Link:
  • 117
    Lenaerts A, Codden T, Henry J-P, Legros F, Ligny G. Comparative pilot study of repeated large volume paracentesis vs the combination of clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol Clin Biol 2005; 29: 1137–1142.
  • 118
    Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatment of refractory ascites of cirrhosis. Scand J Gastroenterol 2006; 41: 118–121.
  • 119
    Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club. Gut 2007; 56: 1310–1318.
  • 120
    Peron J-M, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, et al. Treatment of hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005; 100: 2702–2707.
    Direct Link:
  • 121
    Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 1977; 8: 287–292.
  • 122
    Witzke O, Baumann M, Patschan D, Patschan S, Mitchell A, Treichel U, et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 2004; 19: 1369–1373.
    Direct Link:
  • 123
    Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 1997; 336: 1303–1309.
  • 124
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. HEPATOLOGY 1999; 29: 1690–1697.
    Direct Link:
  • 125
    Esrailian E, Pantangco ER, Kyulo NL, Hu K-Q, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742–748.
  • 126
    Wong F, Pantera L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2004; 40: 55–64.
    Direct Link:
  • 127
    Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005; 20: 1813–1820.
  • 128
    Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, crossover design. HEPATOLOGY 2003; 38: 238–243.
    Direct Link:
  • 129
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin J-L, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. HEPATOLOGY 2002; 36: 374–380.
    Direct Link:
  • 130
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni J-P, Ichai P, et al. Terlipressin in patients with cirrhosis and type I hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923–930.
  • 131
    Sanyal A, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Gastroenterology 2008; 134: 1360–1368.
  • 132
    Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352–1359.
  • 133
    Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935–944.
    Direct Link:
  • 134
    Guevara M, Gines P, Bandi C, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. HEPATOLOGY 1998; 28: 416–422.
    Direct Link:
  • 135
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal function in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363–1368.
  • 136
    Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting liver transplantation. Hepatogastroenterology 2003; 50: 1753–1755.
  • 137
    Gines P, Guevara M. Good news for hepatorenal syndrome. HEPATOLOGY 2002; 36: 504–506.
    Direct Link:
  • 138
    Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med 1973; 289: 1155–1159.
  • 139
    Hoefs JC, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ. Spontaneous bacterial peritonitis. HEPATOLOGY 1982; 2: 399–407.
    Direct Link:
  • 140
    Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. HEPATOLOGY 1984; 4: 1209–1211.
    Direct Link:
  • 141
    Runyon BA, Antillon MR. Ascitic fluid pH and lactate: insensitive and nonspecific tests in detecting ascitic fluid infection. HEPATOLOGY 1991; 13: 929–935.
  • 142
    McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Surawicz CM, Owen RL, eds. Gastrointestinal and Hepatic Infections. Philadelphia, PA: Saunders, 1994: 455–475.
  • 143
    Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. HEPATOLOGY 1990; 12: 710–715.
    Direct Link:
  • 144
    Antillon MR, Runyon BA. Effect of marked peripheral leukocytosis on the leukocyte count in ascites. Arch Intern Med 1991; 151: 509–510.
  • 145
    Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al. Randomized comparative study of efficacy and nephrotoxicity of ampicillin plus tobramycin versus cefotaxime in cirrhotics with severe infections. HEPATOLOGY 1985; 5: 457–462.
    Direct Link:
  • 146
    Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. HEPATOLOGY 2002; 35: 140–148.
    Direct Link:
  • 147
    Runyon BA, Akriviadis EA, Sattler FR, Cohen J. Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci 1991; 36: 1782–1786.
  • 148
    Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano A. Short-course vs long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled trial of 100 patients. Gastroenterology 1991; 100: 1737–1742.
  • 149
    Baskol M, Gursoy S, Baskol G, Ozbakir O, Guven K, Yucesoy M. Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients. J Clin Gastroenterol 2003; 37: 403–405.
  • 150
    Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111: 1011–1017.
  • 151
    Angeli P, Guarda S, Fasolato S, Miola E, Craighhero R, Del Piccolo F, et al. Switch therapy with ciprofloxacin vs intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006; 23: 75–84.
    Direct Link:
  • 152
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–409.
  • 153
    Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56: 597–599.
  • 154
    Fernandez J, Monteagudo J, Bargallo X, Jimenez W, Bosch J, Arroyo V, et al. A randomized unblended pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. HEPATOLOGY 2005; 42: 627–634.
    Direct Link:
  • 155
    Akriviadis EA, McHutchison JG, Runyon BA. Follow-up paracentesis is not usually necessary in patients with typical spontaneous ascitic fluid infection [Abstract]. HEPATOLOGY 1997; 26: 288A.
  • 156
    Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1343–1346.
  • 157
    Soriano G, Teixedo M, Guarner C, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477–481.
  • 158
    Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. HEPATOLOGY 1990; 12: 716–724.
    Direct Link:
  • 159
    Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267–1272.
  • 160
    Blaise M, Paterson D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. HEPATOLOGY 1994; 20: 34–38.
    Direct Link:
  • 161
    Fernandez J, Ruiz del Arbol L, Gomez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131: 1049–1056.
  • 162
    Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122: 595–598.
  • 163
    Rolachon A, Cordier L, Bacq Y, Nousbaum J-B, Franza A, Paris J-C, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. HEPATOLOGY 1995; 22: 1171–1174.
  • 164
    Terg R, Llano K, Cobas S, Brotto C, Barrios A, Levi D, et al. Effect of oral ciprofloxacin on aerobic gram-negative flora of cirrhotic patients: results of short and long term administration with variable does [Abstract]. HEPATOLOGY 1996; 24: 455A.
  • 165
    Bernard B, Grange JD, Khac N, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. HEPATOLOGY 1999; 29: 1655–1661.
    Direct Link:
  • 166
    Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. HEPATOLOGY 2004; 40: 652–659.
    Direct Link:
  • 167
    Ortiz J, Vila C, Soriano G, Minana J, Gana J, Mirelis B, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. HEPATOLOGY 1999; 29: 1064–1069.
    Direct Link:
  • 168
    Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial perinonitis. Gastroenterology 1997; 113: 1289–1294.
  • 169
    Younossi ZM, McHutchison JG, Ganiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. J Hepatol 1997; 27: 295–298.
  • 170
    Novella M, Sola R, Soriano, G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. HEPATOLOGY 1997; 25: 532–536.
    Direct Link:
  • 171
    Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818–824.
  • 172
    Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation. HEPATOLOGY 1995; 21: 1328–1336.
    Direct Link:
  • 173
    Rolando N, Gimson A, Philpott-Howard J, Sahathevan M, Casewell M, Fagan E, et al. Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. J Hepatol 1993; 18: 290–294.
  • 174
    Ho H, Zuckerman MJ, Wassem C. A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. Gastroenterology 1991; 101: 1642–1648.
View Full Article with Supporting Information (HTML) Get PDF (248K)